Renal Artery Pseudoaneurysm After PCNL
Risk Factors, Clinical Features and Outcomes of Management for Renal Artery Pseudoaneurysm After PCNL: A Multicenter Retrospective Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Nikita Astakhov
- Phone Number: +7 (968) 490-46-72
- Email: botkinhospital@zdrav.mos.ru
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Age ≥18 years
Underwent percutaneous nephrolithotomy (PCNL)
Renal artery pseudoaneurysm confirmed by CT angiography
Follow-up ≥30 days post-procedure
Exclusion Criteria:
Known pre-existing renal vascular anomalies or abnormalities
Incomplete medical records (missing key data for analysis)
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients with renal artery pseudoaneurysm after PCNL
Patients who underwent percutaneous nephrolithotomy and subsequent development of renal artery pseudoaneurysm, verified by CT angiography, where the complication could either present with bleeding or have an asymptomatic course
|
Endovascular embolization of a renal artery branch pseudoaneurysm is performed under local anesthesia and sedation.
Following Seldinger puncture of the common femoral artery, an introducer sheath is placed.
Diagnostic renal angiography is performed to localize the pseudoaneurysm and assess the vascular anatomy.
Selective catheterization of the affected branch is achieved using a microcatheter.
An embolic material is delivered into the pseudoaneurysm lumen or into the feeding vessel.
Depending on the anatomical features and operator preference, microcoils (Guglielmi detachable coils or fibered coils), liquid embolic agents (Onyx, glutaraldehyde-acrylic copolymer), or a combination thereof are used.
Completion angiography is performed to confirm complete occlusion of the pseudoaneurysm and preservation of blood flow in the unaffected renal artery branches.
After removal of the introducer sheath, compression of the puncture site is applied for hemostasis.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The number of recorded pseudoaneurysms of the renal artery branches after percutaneous nephrolithotomy (confirmed angiographically)
Time Frame: 1 month
|
1 month
|
|
the proportion of patients with pseudoaneurysm who have the risk factors identified by the study.
Time Frame: 1 month
|
1 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Frequency of hemodynamic instability requiring the use of inotropic agents (unit of measurement: yes/no; measurement instrument: monitoring of blood pressure and heart rate, protocol of inotropic administration).
Time Frame: 1 year
|
1 year
|
|
Volume of blood loss requiring transfusi
Time Frame: 1year
|
1year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Vigen Malkhasyan, Doctor of Medical Sciences, Botkin Moscow Multidisciplinary Scientific and Clinical Center of the Moscow Department of Healthcare; 2 Russian University of Medicine of the Ministry of Health of Russia
- Study Director: Dmitry Pushkar, Academician of the RAS, Botkin Moscow Multidisciplinary Scientific and Clinical Center of the Moscow Department of Healthcare; 2 Russian University of Medicine of the Ministry of Health of Russia
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- Urology20261
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.